BCL2L1 and B-cell chronic lymphocytic leukemia: Navitoclax (ABT-263), a BCL-2/BCL-XL/BCL-W inhibitor, showed strong effects against chronic lymphocytic leukemia (CLL), but also resulted in severe thrombocytopenia7.